Skandinaviska Enskilda Banken AB publ Trims Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Skandinaviska Enskilda Banken AB publ lessened its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 29.4% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 89,047 shares of the company's stock after selling 37,035 shares during the quarter. Skandinaviska Enskilda Banken AB publ owned about 0.31% of Krystal Biotech worth $14,230,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of KRYS. Crossmark Global Holdings Inc. grew its holdings in Krystal Biotech by 25.8% in the third quarter. Crossmark Global Holdings Inc. now owns 2,186 shares of the company's stock worth $398,000 after purchasing an additional 449 shares during the period. Prime Capital Investment Advisors LLC lifted its stake in shares of Krystal Biotech by 93.1% in the third quarter. Prime Capital Investment Advisors LLC now owns 2,591 shares of the company's stock worth $472,000 after buying an additional 1,249 shares in the last quarter. Oppenheimer Asset Management Inc. bought a new position in shares of Krystal Biotech in the third quarter worth approximately $235,000. KBC Group NV lifted its stake in shares of Krystal Biotech by 25.9% in the third quarter. KBC Group NV now owns 642 shares of the company's stock worth $117,000 after buying an additional 132 shares in the last quarter. Finally, Huntington National Bank lifted its stake in shares of Krystal Biotech by 97.6% in the third quarter. Huntington National Bank now owns 573 shares of the company's stock worth $104,000 after buying an additional 283 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company's stock.

Remove Ads

Krystal Biotech Price Performance

Krystal Biotech stock traded up $0.68 during midday trading on Wednesday, reaching $189.18. 175,518 shares of the company traded hands, compared to its average volume of 284,088. The firm has a market capitalization of $5.45 billion, a price-to-earnings ratio of 63.27 and a beta of 0.87. The business has a 50 day moving average of $164.69 and a two-hundred day moving average of $173.58. Krystal Biotech, Inc. has a 12 month low of $141.72 and a 12 month high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping the consensus estimate of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. During the same period last year, the firm earned $0.30 earnings per share. The company's quarterly revenue was up 116.4% on a year-over-year basis. As a group, equities analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on KRYS. HC Wainwright reiterated a "buy" rating and issued a $221.00 target price on shares of Krystal Biotech in a research note on Friday, February 28th. Jefferies Financial Group began coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They issued a "buy" rating and a $245.00 target price on the stock. Citigroup upped their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a research note on Thursday, February 20th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $215.00 target price on shares of Krystal Biotech in a research note on Thursday, February 20th. Finally, Chardan Capital upped their target price on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a research note on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Krystal Biotech has a consensus rating of "Buy" and an average target price of $220.00.

Insiders Place Their Bets

In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. This trade represents a 5.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the sale, the insider now directly owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. This trade represents a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 14.10% of the company's stock.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).